 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12189/12972 (94%)
Visitors : 947124
Online Users : 376
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/16279
|
| Title: | A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access |
| Authors: | Ko, TY;Wu, CC;Hsieh, MY;Yang, CW;Cheng, CH;Chen, CK;Kao, HL |
| Contributors: | Institute of Cellular and Systems Medicine |
| Abstract: | Dialysis vascular access thrombosis poses a substantial challenge for individuals undergoing hemodialysis. The efficacy and safety of apixaban, a direct oral coagulation factor Xa inhibitor, in preventing recurrent access thrombosis have yet to be explored. Here, a multicenter randomized control study (NCT04489849) enrolled hemodialysis patients to evaluate this who underwent successful endovascular thrombectomy within 48 hours. Participants were assigned to standard care or standard care plus apixaban, 2.5 mg twice daily for three months. The trial design involved open-label administration, with independent adjudication of endpoints. The primary efficacy endpoint was recurrent access thrombosis within three months after thrombectomy. A total of 186 patients with well-balanced baseline characteristics were enrolled, 93 randomized to the apixaban group and 93 to the control group. The apixaban group demonstrated a significantly lower rate of access thrombosis at three months than the control group (24.0% vs. 40.8%; hazard ratio, 0.52 [95% confidence interval 0.31-0.88]), along with a significantly better primary patency failure rate (32.2% vs. 49.5%, 0.57 [0.36-0.91]). Safety outcomes showed comparable death rates and major bleeding incidents but significantly higher incidence of minor bleeding in the apixaban group (22.6% vs. 7.5%). The effect of apixaban did not show interaction in subgroups of different access types, antiplatelet usage, severity of comorbidities, or history of thrombosis. Thus, apixaban effectively reduced the risk of recurrent thrombosis in hemodialysis vascular access post-thrombectomy. Despite a minor increase in bleeding adverse effects, the net clinical benefit favors the use of apixaban in this context. |
| Date: | 2024-11-15 |
| Relation: | Kidney International. 2024 Nov 15;Article in Press. |
| Link to: | http://dx.doi.org/10.1016/j.kint.2024.10.023 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0085-2538&DestApp=IC2JCR |
| Appears in Collections: | [吳志成] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB39551132.pdf | | 1387Kb | Adobe PDF | 1 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
